Top Markets
#1 Akedo Akedo +82.13%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.35%
#4 Cross Cross +45.57%
#5 Black Phoenix Black Phoenix +34.20%
#6 Velvet Velvet +32.22%
#7 Cap Cap +21.97%
#8 OVERTAKE OVERTAKE +20.36%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.80%
#10 QANplatform QANplatform +14.83%
Coin of the day
Akedo Akedo
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
BNB Plus Corp. BNB Plus Corp.

BNB Plus Corp.

BNBX
Clasificación en acciones #38647
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a... BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.
Precio por acción
$0.09
Última sincronización: 2026-07-28
Capitalización bursátil
$876.21K
Cambio (1 día)
0.00%
Cambio (1 año)
-97.79%
País
US
Comercio BNB Plus Corp. (BNBX)

Categoría

Healthcare
Ganancias de BNB Plus Corp. (BNBX)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di BNB Plus Corp., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de BNB Plus Corp. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE